Hepatitis C Treatment;Boceprevir "Victrelis" from Gastroenterology and Hepatology

Viral Hepatitis

Journal of Gastroenterology and Hepatology
Special Issue: Australian Gastroenterology Week 2011, 12-15 September 2011, Brisbane Convention & Exhibition Centre, Australia
pages 93–108, September 2011

HCV-Highlights from The Journal of Gastroenterology and Hepatology

To View The Abstracts Listed Below;
Click Here To Download PDF

Boceprevir in addition to standard of care
enhanced sustained virologic responses in
hepatitis C virus genotype-1 with advanced
fi brosis/cirrhosis: subgroup analysis of SPRINT-2
and RESPOND-2 studies

Anemia during treatment with peginterferon
alfa-2b/ribavirin with or without boceprevir is
associated with higher SVR rates: analysis of
previously untreated and previous-treatment failure
patients

Projecting the clinical impact of therapeutic
regimens including boceprevir in previously
untreated adult subjects with chronic hepatitis
C genotype 1

IL28B polymorphism predicts virologic response
in patients with hepatitis C genotype 1 treated
with boceprevir combination therapy

Predictors of sustained virologic response
among genotype 1 previous non-responders and
relapsers to peginterferon/ribavirin when
re-treated with boceprevir plus peginterferon
alfa-2b/ribavirin

Boceprevir resistance-associated variants are
observed more frequently in HCV genotype
1-infected patients with poor response to
peginterferon alfa-2b/ribavirin

Utility of historical data compared to lead-in
response in predicting sustained virologic
response in non-responders and relapsers to
peginterferon/ribavirin when re-treated with
boceprevir + peginterferon alfa-2b/ribavirin

The relationship between tweak and Fn14
expressions in the ductular reaction in
hepatitis C

Impact of residual viremia at week 4 on SVR
during antiviral therapy with pegylated
interferon and ribavirin for chronic HCV
infection

Different definitions of HCV rapid fi brosis post
liver transplant yield insights into the fi brosis
timecourse

Efficacy among North American and European
HCV genotype-1 treatment-naïve and previous
non-responders and relapsers to peginterferon/
ribavirin when treated with boceprevir plus
peginterferon alfa-2b/ribavirin

Hepatitis C treatment induced neutropenia does
not have a negative impact on treatment
outcomes or increase risk of serious infections

Absence of portal hypertension predicts
response to chronic hepatitis C treatment in
patients with bridging fi brosis and cirrhosis

IL28B genotype frequency and early treatment
outcome in hepatitis C patients from a large
Australian single centre

HEPASCORE – a predictor of liver related
mortality in patients with chronic hepatitis C
infection

Overweight and obesity are powerful
independent predictors of both early and
sustained viral response to pegylated-interferon/
ribavirin therapy in hepatitis C

Hepatitis C in pregnancy in Western Australia:
a cross-sectional study

Dangers of IV drug use during hepatitis C
treatment: coincidence or common knowledge?

Evaluation of HCV treatment in rural and remote
areas in Western Australia via telemedicine

One year experience at a regional centre in
treating chronic hepatitis C with combination
anti-viral therapy

Factors predicting progression of hepatitis C
associated fi brosis: a decade long follow-up

Treatment of genotype 1 hepatitis C in a
non-trial setting: surprisingly high sustained
viral response

Treatment of hcv in the setting of
transplantation for hepatocellular carcinoma
(HCC). A missed opportunity?

72 week peg-interferon/ribavirin therapy
improved SVR rates in hepatitis C patients with
incomplete EVR

Special Issue of the Journal of Gastroenterology and Hepatology FoundationSpecial Issue: Australian Gastroenterology Week 2011, 12-15 September 2011, Brisbane Convention & Exhibition Centre, Australia Volume 26, Issue Supplement s4, pages 44–55, September 2011

Check Out The Complete Issue Here;
http://onlinelibrary.wiley.com/doi/10.1111/jgh.2011.26.issue-s4/issuetoc

.